![Cynthia Lavoie](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Cynthia Lavoie
Directeur/Membre du Conseil chez
PROFOUND MEDICAL CORP.
Fortune : 55 856 $ au 31/05/2026
Profil
Cynthia Lavoie is the founder of Delta TpX, Inc. Current positions include Chairman, Secretary & Treasurer at FAAH Pharma, Inc. since 2014; Chairman at Fibrocor Therapeutics, Inc.; Director at Anchor Therapeutics, Inc.; Independent Director at Profound Medical Corp.
since 2021; Director at Morphocell Technologies, Inc.; President, Managing Director & Director at AllosteRx Capital Management (Canada), Inc. since 2018; Director at Apiary Therapeutics, Inc.; General Partner at TVM Life Science Management, Inc. since 2012; and President & Chief Investment Officer at CCRM Enterprises Inc since 2020.
Former roles include Director at Azelon Pharmaceuticals, Inc., Cytochroma, Inc. in 2011, VenGrowth Capital Partners, Inc., Aegera Therapeutics, Inc., VisualSonics, Inc., Interface Biologics, Inc., Mediti Pharma, Inc., Trillium Therapeutics, Inc., Profound Medical, Inc., Kaneq Bioscience Ltd., and Acer Therapeutics, Inc. Education includes an MBA from Rotman School of Management, a doctorate from McGill University, and an undergraduate degree from the University of Ottawa.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
PROFOUND MEDICAL CORP 0,02 % | 10/06/2026 | 8 202 ( 0,02 % ) | 55 856 $ | 31/05/2026 |
Postes actifs de Cynthia Lavoie
| Sociétés | Poste | Début |
|---|---|---|
| PROFOUND MEDICAL CORP. | Directeur/Membre du Conseil | 03/03/2021 |
Apiary Therapeutics, Inc. | Directeur/Membre du Conseil | - |
Technologies Morphocell, Inc.
 Technologies Morphocell, Inc. Pharmaceuticals: MajorHealth Technology Develops cell therapies for treatment of liver disease | Directeur/Membre du Conseil | - |
FAAH Pharma, Inc.
 FAAH Pharma, Inc. BiotechnologyHealth Technology Operates as a project-focused company developing a clinical asset initially for postherpetic neuralgia | Président | 26/06/2014 |
Fibrocor Therapeutics LP
 Fibrocor Therapeutics LP BiotechnologyHealth Technology Develops tissue-specific therapeutics for fibrotic diseases | Président | - |
CCRM Enterprises Inc | President | 01/08/2020 |
AllosteRx Capital Management (Canada), Inc.
 AllosteRx Capital Management (Canada), Inc. Investment ManagersFinance Operates as venture capital company for biotechnology companies | Directeur Général | 01/01/2018 |
TVM Life Science Management, Inc.
 TVM Life Science Management, Inc. Investment ManagersFinance Acts as an alternative investment manager | Private Equity Investor | 01/01/2012 |
Anchor Therapeutics, Inc.
 Anchor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Designs and develops peptide modulators of G protein-coupled receptors | Directeur/Membre du Conseil | - |
Anciens postes connus de Cynthia Lavoie
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
| ░░░░░░░░░ ░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
| ░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
| ░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
Formation de Cynthia Lavoie
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
13
Relations au 1er degré
24
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 24 |
|---|---|
Azelon Pharmaceuticals, Inc.
 Azelon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical drugs for the treatment of osteoporosis | Health Technology |
Trillium Therapeutics, Inc.
 Trillium Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Researches, develops and manufactures medicines & therapies for cancer | Health Technology |
Cytochroma, Inc.
 Cytochroma, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets prescription products for the prevention of vitamin D insufficiency | Health Technology |
Anchor Therapeutics, Inc.
Anchor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Designs and develops peptide modulators of G protein-coupled receptors | Health Technology |
Rotman School of Management
 Rotman School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
VenGrowth Capital Partners, Inc.
 VenGrowth Capital Partners, Inc. Investment ManagersFinance The VenGrowth Funds invest in small and mid-sized private Canadian companies in the technology, life sciences and tradition industries sectors. The Criterion Global Dividend Fund invests in blue-chip multinational companies selected by Merrill Lynch International. The Fund is also available unhedged. The Criterion International Equity Fund is actively sub-advised by The Boston Company. The Fund invests in international stocks outside of North America, with a GARP strategy. It is also available unhedged. The Criterion Water Infrastructure Fund invests globally in companies related to water delivery. The Fund is also available unhedged. The Criterion Global Clean Energy Fund invests in companies involved in the global transition to cleaner energies and lower carbon emissions. The Fund is also available unhedged. The Criterion Diversified Commodities Currency Hedged Fund allows Canadian investors to participate directly in the diversified commodities index UBS Bloomberg CMCI AM. The Criterion US Buyback Fund invests in US companies with the best record of net share buybacks. It is also available unhedged. | Finance |
McGill University
 McGill University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Ottawa
 University of Ottawa Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aegera Therapeutics, Inc.
 Aegera Therapeutics, Inc. BiotechnologyHealth Technology Manufactures and develops drugs | Health Technology |
VisualSonics, Inc.
 VisualSonics, Inc. Medical SpecialtiesHealth Technology Develops vivo micro imaging systems | Health Technology |
Interface Biologics, Inc.
 Interface Biologics, Inc. Information Technology ServicesTechnology Services Provides technologies to medical device manufacturers and drug companies | Technology Services |
Profound Medical, Inc.
 Profound Medical, Inc. Medical SpecialtiesHealth Technology Develops and commercializes a unique, minimally invasive treatment for prostate cancer | Health Technology |
TVM Life Science Management, Inc.
TVM Life Science Management, Inc. Investment ManagersFinance Acts as an alternative investment manager | Finance |
Kaneq Bioscience Ltd.
 Kaneq Bioscience Ltd. BiotechnologyHealth Technology Operates as a biotechnology company focuses on developing treatments for type 2 diabetes | Health Technology |
FAAH Pharma, Inc.
FAAH Pharma, Inc. BiotechnologyHealth Technology Operates as a project-focused company developing a clinical asset initially for postherpetic neuralgia | Health Technology |
Profound Medical Corp.
 Profound Medical Corp. Medical SpecialtiesHealth Technology Develops and markets medical devices focused on prostate cancer | Health Technology |
Mediti Pharma, Inc.
 Mediti Pharma, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops, manufactures and sells pharmaceutical products | Health Technology |
Acer Therapeutics, Inc.
 Acer Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops and commercializes therapies for serious rare and life-threatening diseases | Health Technology |
Fibrocor Therapeutics LP
Fibrocor Therapeutics LP BiotechnologyHealth Technology Develops tissue-specific therapeutics for fibrotic diseases | Health Technology |
Technologies Morphocell, Inc.
Technologies Morphocell, Inc. Pharmaceuticals: MajorHealth Technology Develops cell therapies for treatment of liver disease | Health Technology |
Delta TpX, Inc.
 Delta TpX, Inc. Pharmaceuticals: OtherHealth Technology Develops oncology therapeutics | Health Technology |
AllosteRx Capital Management (Canada), Inc.
AllosteRx Capital Management (Canada), Inc. Investment ManagersFinance Operates as venture capital company for biotechnology companies | Finance |
CCRM Enterprises Inc | |
Apiary Therapeutics, Inc. |
